We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Asks Mid-Cycle for More Data on Clovis Lung Cancer Drug
FDA Asks Mid-Cycle for More Data on Clovis Lung Cancer Drug
The FDA has delayed Clovis Oncology’s bid to approve its new lung cancer treatment, asking for additional trial data that could see the March 30 PDUFA date extended.
